Signal Advisors Wealth LLC Trims Holdings in Elevance Health, Inc. $ELV

Signal Advisors Wealth LLC trimmed its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 88.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 889 shares of the company’s stock after selling 6,716 shares during the quarter. Signal Advisors Wealth LLC’s holdings in Elevance Health were worth $260,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Kemnay Advisory Services Inc. purchased a new position in Elevance Health in the 4th quarter worth about $31,000. J.Safra Asset Management Corp bought a new position in Elevance Health in the 4th quarter worth about $32,000. ORG Partners LLC grew its stake in Elevance Health by 120.4% in the 4th quarter. ORG Partners LLC now owns 108 shares of the company’s stock worth $38,000 after acquiring an additional 59 shares in the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in shares of Elevance Health during the fourth quarter worth approximately $38,000. Finally, Dorato Capital Management bought a new stake in shares of Elevance Health during the fourth quarter valued at approximately $41,000. 89.24% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This trade represents a 1.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.34% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ELV shares. Leerink Partners set a $364.00 price objective on Elevance Health in a research note on Thursday, April 23rd. UBS Group upped their target price on Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a report on Friday, May 22nd. Bank of America increased their price target on Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research report on Thursday, June 4th. Barclays raised their price target on Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Finally, Weiss Ratings raised shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. Fourteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Elevance Health currently has a consensus rating of “Moderate Buy” and an average target price of $416.11.

Elevance Health Stock Performance

Shares of NYSE:ELV opened at $394.86 on Friday. The company has a market capitalization of $85.75 billion, a price-to-earnings ratio of 16.80, a price-to-earnings-growth ratio of 2.19 and a beta of 0.67. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $426.98. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.70. The firm has a 50 day moving average of $383.03 and a 200 day moving average of $349.01.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion during the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.Elevance Health’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, sell-side analysts predict that Elevance Health, Inc. will post 26.92 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, June 25th. Investors of record on Wednesday, June 10th were paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date was Wednesday, June 10th. Elevance Health’s dividend payout ratio is 29.26%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.